To summarise the evidence from randomised controlled trials for the effectiveness and safety of DMARDs in the treatment of juvenile-onset systemic lupus erythematosus, specifically:
- To quantify the effects of DMARDs on disease activity, health related quality of life, risk of permanent organ damage and steroid dose.
- To determine what serious adverse events are associated with DMARDs (using evidence from randomised controlled trials only).
- To report on the tolerability of DMARDs.
This is a protocol.